Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial

The CONCOR-1 Study Group, CONCOR-1 writing committee, View ORCID ProfilePhilippe Bégin, View ORCID ProfileJeannie Callum, Erin Jamula, Richard Cook, Nancy M. Heddle, Alan Tinmouth, Michelle P. Zeller, Guillaume Beaudoin-Bussières, Luiz Amorim, Renée Bazin, Kent Cadogan Loftsgard, Richard Carl, Michaël Chassé, Melissa M. Cushing, Nick Daneman, Dana V. Devine, Jeannot Dumaresq, Dean A. Fergusson, Caroline Gabe, Marshall J. Glesby, Na Li, Yang Liu, Allison McGeer, Nancy Robitaille, Bruce S. Sachais, Damon C. Scales, Lisa Schwartz, Nadine Shehata, Alexis F. Turgeon, Heidi Wood, Ryan Zarychanski, Andrés Finzi, View ORCID ProfileDonald M. Arnold, for The CONCOR-1 Study Group
doi: https://doi.org/10.1101/2021.06.29.21259427
1Section of Allergy, Immunology and Rheumatology, Department of Pediatrics, CHU Sainte-Justine, Montréal, Québec, Canada
Philippe Bégin
1Section of Allergy, Immunology and Rheumatology, Department of Pediatrics, CHU Sainte-Justine, Montréal, Québec, Canada
2Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philippe Bégin
  • For correspondence: philippe.begin.med@ssss.gouv.qc.ca jeannie.callum@kingstonhsc.ca arnold@mcmaster.ca
Jeannie Callum
3Department of Pathology and Molecular Medicine, Kingston Health Sciences Centre and Queen’s University, Kingston, Ontario, Canada
4Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
5Canadian Blood Services, Ottawa, Ontario, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jeannie Callum
  • For correspondence: philippe.begin.med@ssss.gouv.qc.ca jeannie.callum@kingstonhsc.ca arnold@mcmaster.ca
Erin Jamula
8McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Cook
6Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy M. Heddle
5Canadian Blood Services, Ottawa, Ontario, Canada
7Department of Medicine, McMaster University, Hamilton, Ontario, Canada
8McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Tinmouth
5Canadian Blood Services, Ottawa, Ontario, Canada
9Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
10Ottawa Hospital Centre for Transfusion Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle P. Zeller
5Canadian Blood Services, Ottawa, Ontario, Canada
7Department of Medicine, McMaster University, Hamilton, Ontario, Canada
8McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillaume Beaudoin-Bussières
11Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada
12CHUM Research Center, Montréal, Québec, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luiz Amorim
13Hemorio, Rio de Janeiro, Brazil
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renée Bazin
14Héma-Québec, Medical Affairs and Innovation, Québec City, Québec, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kent Cadogan Loftsgard
15Community Advisory Committee representative
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Carl
16Patient representative
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michaël Chassé
17Innovation Hub, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada
18Department of Medicine (Critical Care), Centre Hospitalier de l’Université de Montréal (CHUM), Montréal, Québec, Canada
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa M. Cushing
19Transfusion Medicine and Cellular Therapy, New York-Presbyterian, New York, NY, USA
20Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick Daneman
21Department of Medicine, Division of Infectious Diseases, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana V. Devine
22Canadian Blood Services, Vancouver, British Columbia, Canada
23Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver British Columbia, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeannot Dumaresq
24Département de médecine, CISSS de Chaudière-Appalaches, Lévis, Québec, Canada
25Département de microbiologie-infectiologie et d’immunologie, Faculté de Médecine, Université Laval, Québec, Québec, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean A. Fergusson
5Canadian Blood Services, Ottawa, Ontario, Canada
9Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
26Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Gabe
8McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marshall J. Glesby
27Division of Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Na Li
8McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada
28Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
29Department of Computing and Software, McMaster University, Hamilton, Ontario, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Liu
8McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada
MMath
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allison McGeer
30Department of Microbiology, Sinai Health System, Toronto, Ontario, Canada
31Department of Laboratory Medicine and Pathobiology and Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Robitaille
32Héma-Québec, Montréal, Québec, Canada
33Division of Hematology and Oncology, Department of Pediatrics, CHU Sainte-Justine, Montréal, Québec, Canada
34Department of Pediatrics, Université de Montréal, Montréal, Québec, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce S. Sachais
20Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
35New York Blood Center Enterprises, New York, NY, USA
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damon C. Scales
36Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
37Department of Medicine, Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Schwartz
38Department of Health Research Methods, Evidence & Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadine Shehata
5Canadian Blood Services, Ottawa, Ontario, Canada
39Departments of Medicine, Laboratory Medicine and Pathobiology, Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
40Division of Hematology, Mount Sinai Hospital, Toronto, Ontario, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexis F. Turgeon
41Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Faculty of Medicine, Université Laval, Québec City, Québec, Canada
42CHU de Québec – Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit, Trauma-Emergency - Critical Care Medicine, Université Laval, Québec City, Québec, Canada
MD, MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heidi Wood
43Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan Zarychanski
44Department of Internal Medicine, Sections of Hematology/Medical Oncology and Critical Care, University of Manitoba, Winnipeg, Manitoba, Canada
MD, MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrés Finzi
11Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada
12CHUM Research Center, Montréal, Québec, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald M. Arnold
7Department of Medicine, McMaster University, Hamilton, Ontario, Canada
8McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada
MD, MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Donald M. Arnold
  • For correspondence: philippe.begin.med@ssss.gouv.qc.ca jeannie.callum@kingstonhsc.ca arnold@mcmaster.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The efficacy of convalescent plasma for COVID-19 is unclear. While most randomized controlled trials have shown negative results, uncontrolled studies have suggested that the antibody content may influence patient outcomes.

We conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 days of respiratory symptom onset. Patients were allocated 2:1 to 500 mL of convalescent plasma or standard of care. The composite primary outcome was intubation or death by 30 days. The effect of convalescent plasma antibodies on the primary outcome was assessed by logistic regression.

The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility. 940 patients were randomized and 921 patients were included in the intent-to-treat analysis. Intubation or death occurred in 199/614 (32.4%) in the convalescent plasma arm and 86/307 (28.0%) in the standard of care arm; relative risk (RR) 1.16 (95% confidence interval (CI) 0.94-1.43; p=0.18). Patients in the convalescent plasma arm had more serious adverse events (33.4% vs. 26.4%; RR=1.27, 95% CI 1.02-1.57, p=0.034). The antibody content significantly modulated the therapeutic effect of convalescent plasma. In multivariate analysis, each standard log increase in neutralization or antibody-dependent cellular cytotoxicity independently reduced the potential harmful effect of plasma (OR=0.74; 0.57-0.95 and OR=0.66; 0.50-0.87, respectively), while IgG against the full transmembrane Spike protein increased it (OR=1.53, 95% CI 1.14-2.05).

Convalescent plasma did not reduce the risk of intubation or death at 30 days among hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavourable antibody profiles may be associated with worse clinical outcomes compared to standard care.

Trial registration CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1); NCT04348656; https://www.clinicaltrials.gov/ct2/show/NCT04348656

Competing Interest Statement

PB reports payments to his institution from Canadian Institutes of Health Research, Ministere de l'economie et de l'innovation du Quebec, Fondation du CHU Sainte-Justine, Fondation du CHUM, and Fonds de Recherche du Quebec en Sante; JC reports research grants from Canadian Institutes of Health Research, University of Toronto, Sunnybrook Health Sciences Centre, and Canadian Blood Services; NMH reports research project funding unrelated to this study from Canadian Institutes of Health Research and Canadian Blood Services, honorarium for educational events unrelated to this study from CSL Behring Canada, and participation on a Data Safety Monitoring Board or Advisory Board for Canadian Blood Services (Scientific Advisory Committee); MPZ reports consulting fees from Canadian Blood Services in her role as a Medical Officer but receives no direct benefit from the study results; GBB reports a grant from Canadian Institutes of Health Research for Masters students; MMC reports consulting fees from Octapharma, participation in a data safety monitoring board or advisory board for Cerus and Haemonetics, and receipt of equipment, materials, drugs, medical writing, gifts or other services by her institution from Cerus; ND reports grants from AFP Innovation Fund Award Sunnybrook Health Sciences Centre, and University of Toronto; MJG reports payments to his institution from Regeneron, consulting fees from Regeneron and ReAlta Life Sciences, and participation on a Data Safety Monitoring Board or Advisory Board for Enzychem and Sobi; BSS reports employment by New York Blood Centre (but receiving no direct benefit from study participation); LS reports a leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid (Member of the Ontario Bioethics Table for COVID-19); NS reports payment to her institution from the MSH Foundation for CONCOR; AF reports funding from Fondation du CHUM, Ministere de l'economie et de l'Innovation du Quebec, and Canadian Institutes of Health Research. All other authors declare no competing interests.

Clinical Trial

NCT04348656

Clinical Protocols

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05235-3

Funding Statement

Funding for the study was provided by Canadian Institutes of Health Research - COVID-19 May 2020 Rapid Research Funding Opportunity - Operating Grant; Ontario COVID-19 Rapid Research Fund; Toronto COVID-19 Action Initiative 2020 (University of Toronto); University Health Network Emergent Access Innovation Fund; University Health Academic Health Science Centre Alternative Funding Plan (Sunnybrook Health Sciences Centre); Ministere de l'Economie et de l'Innovation (Quebec);  Saskatchewan Ministry of Health; University of Alberta Hospital Foundation; Alberta Health Services COVID-19 Foundation Competition; Sunnybrook Health Sciences Centre Foundation; Fondations CHU Ste-Justine; Fondation du CHUM; The Ottawa Hospital Academic Medical Organization; The Ottawa Hospital Foundation COVID-19 Research Fund; Sinai Health System Foundation and McMaster University. These did not have any role in the writing of the manuscript or the decision to submit it for publication. The authors did not receive payments from any pharmaceutical company or other agency to write this article.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by Clinical Trials Ontario (Research Ethics Board of Record: Sunnybrook Health Sciences Centre), project #2159; the Quebec Ministry of Health and Social Services multicenter ethics review (REB of Record: Comite d'ethique de la recherche du CHU Sainte-Justine), project #MP-21-2020-2863; the Weil Cornell Medicine General Institutional Review Board, protocol number 20-04021981; as well as the Comissao Nacional de Etica em Pesquisa, approval 4.305.792.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵† Please refer to the appendix for the complete list of CONCOR-1 investigators and collaborators

  • Reprint Requests: Dr. Donald M. Arnold, McMaster Centre for Transfusion Research, McMaster University HSC-3H50, 1280 Main St. West, Hamilton, Ontario, L8S 4K1; Email: arnold{at}mcmaster.ca

  • Grant Support: Canadian Institutes of Health Research – COVID-19 May 2020 Rapid Research Funding Opportunity – Operating Grant; Ontario COVID-19 Rapid Research Fund; Toronto COVID-19 Action Initiative 2020 (University of Toronto); University Health Network Emergent Access Innovation Fund; University Health Academic Health Science Centre Alternative Funding Plan (Sunnybrook Health Sciences Centre); Ministère de l’Économie et de l’Innovation; Fond de Recherche du Québec en Santé; Saskatchewan Ministry of Health; University of Alberta Hospital Foundation; Alberta Health Services COVID-19 Foundation Competition; Sunnybrook Health Sciences Centre Foundation; Fondations CHU Ste-Justine; The Ottawa Hospital Academic Medical Organization; The Ottawa Hospital Foundation COVID-19 Research Fund; Fondation du CHUM; Sinai Health System Foundation and McMaster University.

Data Availability

De-identified individual patient data with the data dictionary that underlie the reported results will be made available upon request if approved by the CONCOR-1 Steering Committee. Proposals for access should be sent to arnold@mcmaster.ca.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 03, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial
The CONCOR-1 Study Group, CONCOR-1 writing committee, Philippe Bégin, Jeannie Callum, Erin Jamula, Richard Cook, Nancy M. Heddle, Alan Tinmouth, Michelle P. Zeller, Guillaume Beaudoin-Bussières, Luiz Amorim, Renée Bazin, Kent Cadogan Loftsgard, Richard Carl, Michaël Chassé, Melissa M. Cushing, Nick Daneman, Dana V. Devine, Jeannot Dumaresq, Dean A. Fergusson, Caroline Gabe, Marshall J. Glesby, Na Li, Yang Liu, Allison McGeer, Nancy Robitaille, Bruce S. Sachais, Damon C. Scales, Lisa Schwartz, Nadine Shehata, Alexis F. Turgeon, Heidi Wood, Ryan Zarychanski, Andrés Finzi, Donald M. Arnold, for The CONCOR-1 Study Group
medRxiv 2021.06.29.21259427; doi: https://doi.org/10.1101/2021.06.29.21259427
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial
The CONCOR-1 Study Group, CONCOR-1 writing committee, Philippe Bégin, Jeannie Callum, Erin Jamula, Richard Cook, Nancy M. Heddle, Alan Tinmouth, Michelle P. Zeller, Guillaume Beaudoin-Bussières, Luiz Amorim, Renée Bazin, Kent Cadogan Loftsgard, Richard Carl, Michaël Chassé, Melissa M. Cushing, Nick Daneman, Dana V. Devine, Jeannot Dumaresq, Dean A. Fergusson, Caroline Gabe, Marshall J. Glesby, Na Li, Yang Liu, Allison McGeer, Nancy Robitaille, Bruce S. Sachais, Damon C. Scales, Lisa Schwartz, Nadine Shehata, Alexis F. Turgeon, Heidi Wood, Ryan Zarychanski, Andrés Finzi, Donald M. Arnold, for The CONCOR-1 Study Group
medRxiv 2021.06.29.21259427; doi: https://doi.org/10.1101/2021.06.29.21259427

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1747)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10780)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2933)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1918)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12496)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2780)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (554)
  • Occupational and Environmental Health (597)
  • Oncology (1454)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (379)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2630)
  • Public and Global Health (5338)
  • Radiology and Imaging (1002)
  • Rehabilitation Medicine and Physical Therapy (594)
  • Respiratory Medicine (722)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)